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The  rosette technique  is a  method  of visualizing receptors on  cell surfaces.  The 
principle is the following: The suspected receptor-bearing cells are mixed with signal 
cells which carry the corresponding receptor-binding substance on their surface. That 
substance is either naturally occurring on it or artificially  coupled to it. The receptor- 
bearing cells will then bind the signal cells around their surface and form "rosettes." 
It  has  been  shown  that  there  exists a  small population  of  spontaneous  rosette- 
forming lymphocytes (RFL) 1 in the unimmunized mouse corresponding to a  certain 
antigen, and that the  size of  this population will rise after immunization with  that 
antigen (1). These rosettes are called immune rosettes. The RFL consist of antibody- 
producing cells and of antigen-sensitive cells of bone marrow origin (B lymphocytes) 
(1). Whether th)~mus-derived (T)  lymphocytes can form  rosettes remains uncertain 
(2); some data support this view. Spontaneous RFL have immunoglobulin receptors, 
and their rosette-forming ability can be blocked by pretreating the lymphocytes with 
anti-Ig sera or anti-lymphocyte sera (ALS). There  is a  positive correlation between 
the immunosuppressive effect in man of ALS and its blocking capacity of these RFL 
(3). Such blocking is thus used for testing ALS before use in clinical practice. 
In  1970  some workers (4-7)  observed that sheep red blood cells (SRBC)  formed 
spontaneous rosettes with human lymphocytes (E rosettes) in a very high percentage, 
too high to be explained as being caused by binding to immunocompetent cells reac- 
tive against SRBC. 
In the present work the E-binding lymphocytes have been investigated for 
Ig  determinants  on  their  surface  and  for  erythrocyte-antibody-complement 
(EAC)-binding  capacity.  These  complement-covered  RBC  will  bind  to  the 
lymphocytes by  the  receptor for  activated Ct3  (8).  Further  characterization 
of E  rosette formation is also presented. 
Materials  and Methods 
Lymphocytes.--Purification  was  carried out on a  Ficoll-Isopaque gradient. 9  g  of Ficoll 
(Pharmacia Fine Chemicals,  Inc., Stockholm,  Sweden) was  dissolved in 100 ml of distilled 
1 Abbreviations used in this paper: ALS, anti-lymphocyte  sera; B lymphocytes, lymphocytes 
of bone marrow origin; BSS, balanced salt solution; EAC, erythrocyte-antibody-complement; 
FITC, fluorescein isothiocyanate; HRBC, human red blood cells; HTL, intracellular thymus- 
specific antigen; PBS, phosphate buffer solution;  RFL, rosette-forming  lymphocytes; SRBC, 
sheep red blood cells; T lymphocytes, thymus-derived lymphocytes. 
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water. 20 ml of Isopaque (Nyegaard  & Co., Oslo,  Norway) was mixed with 25 ml of distilled 
water. 96 parts of Ficoll was mixed with 40 parts of Isopaque. 3 ml of the gradient was over- 
layered  with  6-8  ml  of  whole  blood  in  plastic  tubes  and  spun  at  850  g  for  30  rain 
at 4°C.  The cells were removed from the interface and the concentration was adjusted  to 
4  X  106/ml in balanced salt solution (BSS; Milit~rapoteket, Stockholm, Sweden). 
SRBC.--SRBC were stored at 4°C in Alsever's solution l:l  and used until hemolysis oc- 
curred. Before use the cells were washed twice and adjusted to a  0.5% suspension (approxi- 
mately 80 X  106/ml) in BSS. 
Test Procedure for E Rosettes.--0.25 ml of the lymphocyte suspension was mixed with 0.25 
ml of 0.5% SRBC and incubated at 37°C  for 5 min. The mixed cell suspension was spun at 
200 g for 5 min and then incubated in ice for 1--2 hr. The supernatant was removed and the 
top layer of the pellet was gently resuspended by shaking. One drop of the cell suspension was 
mounted on to a glass slide, covered by a cover sIip, and sealed. 200 lymphocytes were counted, 
and all lymphocytes binding more than three SRBC were considered positive. 
Labeling of Ig-Bearing Lymphocytes.--2  X  106 of lymphocytes were incubated with one 
drop of a  polyvalent rabbit anti-human Ig serum (anfi-IgG, IgA, IgM, kappa, and lambda; 
Cappel Laboratories, Downingtown, Pa.) and then washed twice with BSS. A second incubation 
was performed with one drop of a  sheep anti-rabbit Ig serum (State Bacteriological Labora- 
tories, Stockholm, Sweden) and washed twice with BSS. Both antisera were conjugated with 
fluorescein isothiocyanate (FITC).  The pellet was resuspended in one drop of glycerol: PBS 
(1 : i). 200 cells were counted, and all ceils displaying more than two to three sharply stained 
spots were considered positive.  The highest serum concentration failing to  give nonspecific 
staining was used. 
T~st Procedure for EA C Rosettes.--Human  red blood cells (HRBC) from heparinized whole 
blood were washed twice with BSS. A 5% suspension in BSS was reacted with a rabbit anti- 
HRBC  serum diluted 1:1000  (inactivated whole serum prepared by injecting AB ~- HRBC 
in a rabbit). 5 ml of the antiserum was mixed with 5 ml of the cell suspension and incubated 
at  37°C  for  1  hr.  The  cells  were  washed  twice  in  BSS.  5  ml  of  human  C'  (fresh 
serum) was added in a concentration of 1 : 10 to the 5 ml cell suspension and incubated at 37°C 
for 1 hr. The ceils were finally washed twice and adjusted to a 0.5% suspension (approximately 
80 X  106/ml). Further procedure was followed as described for E  rosette formation with the 
exception that the rosettes were resuspended by vigorous mixing with a whirl-mixer. 200 ceils 
were counted under a  sealed cover slip. 
Test Procedure with Mixed E Fitc and EAC.--SRBC (or E) were conjugated with FITC  as 
follows: 0.5 ml of packed SRBC were washed twice in 0.9% NaC1. The cells were mixed with 
3.5 ml of 0.9% NaCI, pH 9.0-9.5.  1.4 mg of FITC in 1.0 ml of 0.9% NaCl with the same pH 
was then added, and the suspension was kept at room temperature for  1 hr with occasional 
shaking. The cells were washed three to four times. 
E and EAC were then mixed to a 0.5% solution. Incubation for rosette formation was per- 
formed as for E rosettes. 200 cells were counted under a sealed cover slip. 
RESULTS 
Lymphocytes Forming E  Rosettes.--The percentage of E  rosettes from periph- 
eral blood varied from 52  to 81%  in eleven cases  (Tables I-III).  Almost  100% 
of the thymocytes formed E  rosettes. The percentage of E-binding lymphocytes 
varied slightly according to their location on the glass slide.  The figures in the 
tables  are  from representative fields with  little cell  clumping  and healthy  ap- 
pearing  cells.  The  binding  between  lymphocytes  and  SRBC  is  very  weak  so 
care must  be taken  when resuspending the rosettes.  No movement  of the cells 
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(less  than  5%  of  granulocytes  and  monocytes)  is  demonstrated  by  May- 
Griinwald Giemsa-stained smears. By spinning down the rosettes in a  cytocen- 
TABLE  I 
Lymphocytes from Peripheral Blood 
Donor No.  Percentage of  Percentage of  Percentage  of both IG- 
E-binding cells  IG-bearing cells  bearing  and E-binding  cells 
%  %  % 
1  60  44  0 
2  76  20  0 
3  52  43  0 
4  73  28  0 
5  68  35  0 
6  75  20  0 
Donors 1-5 represent young healthy donors. Donor 6 is a female patient with sarcoidosis 
(age  21).  In  this case lymphocytes from both peripheral blood and  thymus  were studied. 
Each test was performed separately. 
TABLE  II 
Lymphocytes from Thymus 
Donor No.  Percentage of E-binding  cells  Percentage  of IG-bearing cells 
%  % 
6  98  0 
7  99  N.D. 
Case 6 is the same as No. 6 in Table I. Case 7 is a male patient with sarcoidosis (age  21). 
Each test was performed separately. 
TABLE  III 
Lymphocytes from Peripheral Blood 
Donor  Percentage  of  Percentage  of  Percentage of both  Percentage  of 
No.  EFite-binding  cells  EAC-binding  Percentage  of  IG-bearing  and  both EFitc- and 
cells  [G-bearing  cells  EFite-binding  cells  EAC-binding  cells 
%  %  %  %  % 
8  60  27  25  0  0 
9  65  30  34  0  0 
10  68  33  31  0  0 
11  81  25  22  0  0 
12  71  27  26  0  0 
Donors 8-12  represent young healthy donors. Each test was performed separately. 
trifuge (IW.A.  Stockholm,  Sweden),  it  is  also  shown  that  rosette formation 
only occurs around cells with lymphocyte morphology. After 1  2 hr incubation 
in an ice bath,  rosettes were observed with more than one layer of SRBC  sur- 
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Lymphocytes Forming EAC Rosettes.--In  five cases studied between  25  and 
33%  of lymphocytes were found  to form  EAC  rosettes  (Table III).  In  these 
rosettes the HRBC  are very tightly bound to the lymphocytes and the rosettes 
were  shaken  vigorously before  investigation. These  rosettes  can  also be  pro- 
duced and kept at 37°C, in contrast to the E  rosettes. 
Lymphocytes Forming E Rosettes and Lymphocytes Forming EAC Rosettes.- 
No mixed rosettes were observed where the lymphocytes would bind both SRB C 
and HRBC  (Table III). This was possible to determine as the HRBC  and the 
SRBC differ in size. Occasionally the rosettes were in clumps and it was difficult 
to exclude mixing of the signal cells bound  to the surface.  This difficulty was 
overcome by labeling the  SRBC  with  FITC  which  allowed inspection of the 
TABLE IV 
Lymphocytes from Peripheral Blood (CLL) 
Donor No.  Percentage of E-binding cells  Percentage of IG-bearing cells 
1  4  92 
2  6  87 
3  3  84 
Case 1 is a male age 67. Case 2 is a female age 57. Case 3 is a male age 63. All three pa- 
tients have chronic lymphatic leukemia (CLL). Each test was performed separately. 
rosettes in UV light. The EAC rosettes were observed as black spaces between 
the evenly spread SRBC ~itc and  SRBC ri~c rosettes. 
Lymphocytes  Bearing Ig Determinants.--20-44%  of peripheral lymphocytes 
were stained but  no  thymocytes (Tables I-III). All cells that displayed more 
than  two to three brightly stained spots were considered positive. 
L ymphocytes Forming E Rosettes and Lymphocytes Bearing Ig Determinants.- 
No E  rosette-forming lymphocytes were found that were also carrying Ig deter- 
minants  on  their surface  (Tables I  and  III). Most of the lymphocyte surface 
was available for inspection as the SRBC  were mostly bound in a  ring around 
the  surface  and  did not  cover it completely. Some nonrosette-forming leuko- 
cytes that were also negative for anti-Ig labeling were observed. This might be 
due to the small contamination of granulocytes and monocytes. No inhibition 
of E  rosette formation occurred after anti-Ig treatment of the lymphocytes. 
Clinical  Tests.~ymphocytes  from  three  patients  with  chronic  lymphatic 
leukemia were examined. These lymphocytes were uniformly tow in E  binding 
and correspondingly high when tested with anti-Ig ser~ (Table IV). 11 Burkitt 
lymphoma lines grown in vitro and  three biopsies were examined  and showed 
no binding of E  or EAC. Some lines were positive for anti-Ig labeling. 
Further Characterization of 1'2 Rosette Formation.--Lymphocytes  pretreated 
with 3.2 mM sodium iodoacetate for 30 min at 37°C failed to form rosettes. The 
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Rosette formation was reduced in Ca  ++- and Mg++-free buffer and was com- 
pletely  impaired  in  the  presence  of  ethylenediaminetetraacetate  (EDTA). 
Rosette  formation  was  optimal  at  pH  7.0-8.0  and  dropped  considerably  at 
higher or lower pH. 
Pretreatment of lymphocytes with 0.25 % trypsin for 30 min at room temper- 
ature abolished their rosette-forming capacity while maintaining good viability 
(Tables V  and VI). These E-binding tests  were performed under slightly dif- 
TABLE V 
RegenerationqfRosetteFormatfonafterTrypsin  Treatment 
Incubation 
Percentage of cells forming E  rosettes 
Trypsin treated  Untreated 
%  % 
None  1  40 
At 4°C  1  29 
At 37°C  27  20 
Trypsin treatment of lymphocytes. 
TABLE VI 
Treatment  of  Trypsinized  Lymphocytes  with  Serum 
Percentage of cells forming E rosettes 
Treatment 
Trypsin treated  Untreated 
%  % 
Human serum (fresh)  2  47 
Human serum (heat inactivated)  1  53 
Fetal calf serum (heat inactivated)  1  34 
None  1  36 
Treatment  of trypsinized  lymphocytes with  human serum  or fetal  calf serum. 
ferent conditions from those described  above which explains  the low  percent- 
ages. Trypsinization of SRBC had no effect. When incubated  at 37°C in  com- 
plete medium with  fetal  calf  or human  AB  serum  for  18  hr,  rosette-forming 
capacity was restored  (Table  V).  During incubation  at  4°C lymphocytes did 
not recover rosette formation.  Regeneration of rosette  formation was not pre- 
vented in  the  presence  of  cyclohexamide  in  a  concentration which inhibited 
90%  of protein  synthesis (25 vg/ml). 
Rosette  formation  could  not  be  conferred  to  trypsinized  lymphocytes by 
treating them for 1 hr in 50% flesh human serum or fetal calf serum (Table VI). 
The same  result  was obtained  when  lymphocytes were  treated  with  medium 
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DISCUSSION 
Coombs et al. (4) found that SRBC formed rosettes with human lymphocytes 
in a very high percentage, too high to be explained by binding to immunocom- 
petent cells reactive against SRBC. Only living cells could form this nonimmune 
type of rosette. No inhibition occurred when the lymphocytes were pretreated 
with anti-Lg sera. 
Brain et  al.  (5,  6)  showed  that such  rosette formation is uncorrelated  with 
serum  anti-SRBC  agglutinin  levels. Lymphocytes from  umbilical  cord  blood 
could also form rosettes, as could lymphocytes from baboons and vervet mon- 
keys.  Red  blood  cells from some other  species studied  (rat,  rhinoceros,  and 
warthog) would not bind to human lymphocytes in the same high percentage. 
When correlating the inhibition, cytotoxic, and leukoagglutinating titers of ALS 
(raised in horses) obtained at different times after immunization with the sur- 
vival time of skin allografts on vervet monkeys, it was found that the peak of 
the inhibition titer appeared to provide a good index of the immunosuppressive 
activity. These peaks were of short duration  in contrast to the cytotoxic and 
agglutinating titers. 
Bianco et al.  (7)  found that maximal adherance occurred when first contact 
between the cells was established  at 37°C  and was followed by incubation  at 
low  temperature. With  further incubation  at 37°C  the rosettes disintegrated. 
In five cases where they studied lymphocytes and thymocytes from the same 
donors,  a  significantly higher  percentage of E  rosettes was found  among the 
thymocytes. RBC from the horse, ox, rabbit, guinea pig, and mouse could not 
form rosettes. 
Recently Yata et a13 studied the presence of an intracellular thymus-specific 
antigen  (HTL) in E- and EAC-binding human lymphocytes. They found that 
E  adhered to the majority of thymocytes and to 10-30% of lymphocytes from 
peripheral tissues. Almost all E-binding cells were HTL positive. In contrast, 
cells binding  EAC  were HTL negative.  From these data they conclude  that 
E-binding cells are of thymus origin. Unfortunately SRBC were used for pro- 
ducing EAC which leaves some doubt about the receptor involved. In the thy- 
mus for instance they demonstrated approximately 40g  of EAC-binding cells. 
We have found approximately 52-81~  of E-binding lymphocytes in periph- 
eral blood with our test conditions  (Tables I-III). This is a higher percentage 
than  has  been  found  by  the  previous  investigators  (4-7).  Using  a  double 
immunofluorescent  labeling  technique  for  detecting  lymphocytes carrying  a 
high  density  of immunogtobulin determinants  on their  surface, it was shown 
that these latter cells could not form E  rosettes. By extension from studies in 
2 Yata, J., I. Taukimoto, and T. Tachibana.  1971. Human b'mphocyte subpopulations; 
human thymus-lymphoid tissue (HTL) antigen positive lymphocytes forming rosettes with 
sheep erythrocytes and HTL antigen negative lymphocytes interacting with antigen-antibody- 
complement complexes. Submitted to Clin. Exp.  Immunol. M.  JONDAL~ G.  ttOLM~ AND H.  WIGZELL  213 
the mice they are considered B  cells (9). 3 It was also shown that EAC-binding 
lymphocytes, which are also considered B  cells (10), did not bind SRBC. This 
was done by a mixed rosette procedure where C' was fixed to HRBC. When lym- 
phocytes were mixed with SRBC and HRBC no mixed rosettes occurred. Since 
the percentage of cells positive for the B  markers and  the percentage of cells 
binding SRBC added together equal approximately 100%, it is suggested  that 
all or at least a major population of all human thymus-derived lymphocytes will 
bind to SRBC under these conditions. It is also noted that the percentage Ig- 
carrying cells roughly corresponds with  the percentage of EAC-binding  cells. 
This would imply that man in this respect resembles mice and carried the Ct3 
receptor on all bone marrow-derived tymphocytes. When testing three cases of 
chronic  lymphatic leukemias,  their  lymphocytes were  found  to  bind  E  very 
poorly and to be correspondingly highly positive for anti-Ig. These cases might 
therefore be called  B  lymphocyte diseases.  This is in  line with  the finding of 
Wilson et al. (9). Also three Burkitt biopsies and eleven Burkitt lines grown in 
vitro were tested.  They were uniformly negative for E and EAC binding. Some 
were positive for anti-Ig. 
The E rosettes are not formed by virtue of Ig receptors, and they show much 
weaker binding characteristics than the immune rosettes. Only living cells are 
rosette forming and sodium iodoacetate (an inhibitor of glycolysis) blocks the 
reaction.  At 37°C  the E  rosettes will  disintegrate.  Rosette formation requires 
bivalent  positive  ions  and  can  be  abolished  by EDTA.  Pretreatment  of  the 
lymphocytes with trypsin removed their E-binding capacity. Trypsinized lym- 
phocytes put into culture will regenerate the rosette-forming ability which can- 
not be restored by merely treating the lymphocytes with serum. Possibly the 
rosettes are formed by virtue of a rapidly released or metabolized substance on 
the cell surface which behaves as a trypsin-sensitive structure. 
As a marker the rosette foimation has some disadvantages. The binding is so 
weak that the technical conditions have to be optimal. Even then,  it may be 
impossible to exclude that some rosettes disintegrate on their way to the micro- 
scope. 
Possible implications of this human T  lymphocyte marker are several:  (a) 
Reclassification of human lymphoid diseases according to the T  and B cell con- 
cept. This might be of value for better understanding  of etiologic and patho- 
genetic mechanisms. (b) It may also be valuable knowledge from a therapeutic 
point of view as an additional means of characterizing the immunological status 
in  man  during  other  nonimmunological  diseases  and  after different kinds  of 
treatment  (X-ray,  cortisone,  etc.).  (c)  Blocking  of  rosette  formation  might 
provide a more sensitive test for ALS than the presently used blocking test with 
imnmne rosettes since the latter are only present at the 1% level. Perhaps block- 
3 Froland, S. S., and J. B. Natvig. 1971. Surface-bound immunoglobulins on lymphocytes 
from normal and immunodeficient humans. Submitted to Scand. J. Immunol. 214  A HUMAN T LYMPItOCYTE MARKER 
ing of E  rosette  formation  also  might be  more  specific  since  it  has  not  been 
proven that immune rosettes comprise T  cells. These speculations are based on 
the assumptions that the T  cells are the most important cells during these con- 
ditions.  (d) As a possible way to enrich human B cells. T  cells have hitherto not 
been shown to bind to antigen-coated columns. Perhaps the affinity between T 
lymphocytes and  SRBC  under  certain  conditions  can be used for nonspecific 
retention  of T  cells.  The T  cells may stick to SRBC fixed on to some column 
material  and could then be eluted by incubating the  column at  37°C. 
SUMMARY 
By using the two criteria  (a) high density of immunoglobulin determinants 
on the cell surface and  (b)  presence of receptors for C'3 on the cell  surface for 
defining bone marrow-derived lymphocytes, it  is indirectly  shown  that  all  or 
at least  a major population of human thymus-derived lymphocytes under cer- 
tain  conditions  will  form  nonimmune  rosettes  with  sheep  red  blood  cells 
(SRBC).  Almost  all  thymocytes tested  from  two different  donors formed ro- 
settes.  The SRBC rosettes  are not formed by virtue of immunoglobulin recep- 
tors  and form only around living cells.  Positive bivalent  ions are required  for 
rosette formation since EDTA will block rosette formation. Sodium iodoacetate 
will  also block  rosette  formation demonstrating  the  dependence  on  an  intact 
glycolytic pathway.  Rosette  formation is ternperature  dependent  and will not 
appear  at  37°C.  Trypsin treatment  of lymphocytes will  abolish  their  SRBC- 
binding  ability  which  cannot  be  restored  by treating  them  with  fresh  donor 
serum or fetal calf serum, but which will reappear after culturing the lympho- 
cytes.  It is  snggested  that  these  rosettes  are formed by a  rapidly  released  or 
metabolized  receptor  substance  on the living cell  surface which behaves  as  a 
trypsin-sensitive structure ploduced by the cells themselves. 
These investigations were conducted under contract No. NIH-NCI-E-69-2005  within  the 
Special Virus Cancer Program of the National Cancer Institute,  National Institutes of Health, 
U.S. Public Health Service and with grants from the Swedish Cancer Society and Karolinska 
Institutet, Stockholm, Sweden. 
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